Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a strategic focus on autonomous labs, a growing area with interest from key tech sectors, but lacks detailed financial performance data. The absence of revenue, margins, and cash flow information, combined with competition risks, tempers optimism. The market reaction is expected to be neutral, as excitement about innovation is balanced by uncertainties and competition.
Key Financial Performance
Revenue Not explicitly mentioned in the provided text.
Margins Not explicitly mentioned in the provided text.
Cash Flow Not explicitly mentioned in the provided text.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Autonomous Labs: Focus on investing to win the category of autonomous labs, specifically Nebula, which aims to replace traditional lab benches in biological science.
Interest in Autonomous Labs: Growing attention from Silicon Valley companies, AI Frontier labs, and government discussions about the application of AI models in science.
Strategic Focus on Autonomous Labs: Shift in focus towards autonomous labs as a key area of growth and innovation for 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges risks and uncertainties associated with forward-looking statements, as highlighted in their SEC filings.
Competition in autonomous labs: The CEO mentions increasing competition in the autonomous labs category, with new companies in Silicon Valley entering the space and growing interest from AI Frontier labs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Autonomous Labs: Ginkgo's focus in 2026 will be on investing to win the category of autonomous labs. The company sees autonomous labs like Nebula replacing traditional lab benches, which is where nearly all of biological science is done today. This category has been growing in attention, with new companies in Silicon Valley pursuing it and increased interest from AI Frontier labs about the application of AI models in science via autonomous labs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bioworks Holdings
CEO Director
COO CEO
Chief Financial
Co COO
Co Founder
Coen Chief
Communications Ownership
Director Coen
EDT Senior
Financial Officer
Founder Co
Ginkgo Bioworks
Ginkgo Kelly
GinkgoResults mail
Holdings Inc
Inc Senior
Kelly Co
Manager Communications
Officer PM
Ownership Ginkgo
Ownership Kelly
Ownership evening
PM EDT
Senior Manager
advance GinkgoResults
bench science
evening Senior
insight lab
mail Co
science today
today QA
DNA Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call highlights a strategic focus on autonomous labs, a growing area with interest from key tech sectors, but lacks detailed financial performance data. The absence of revenue, margins, and cash flow information, combined with competition risks, tempers optimism. The market reaction is expected to be neutral, as excitement about innovation is balanced by uncertainties and competition.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call reveals improvements in financial metrics, including reduced operating losses and cash burn due to restructuring. Although revenue decreased, optimistic guidance and strategic initiatives in AI and robotics present potential growth avenues. The Q&A section highlights positive reception of new services and potential revenue tailwinds. However, management's vague response on U.S. onshoring introduces some uncertainty. Overall, the positive elements, such as improved financial health and strategic growth plans, outweigh negatives, suggesting a likely positive stock price movement.
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
Unknown11-6
Despite strong cash reserves and cost management, the company faces challenges with declining revenues and increased losses in Cell Engineering. Positive aspects include restructuring efforts, optimism about government partnerships, and new product launches. However, the lack of significant revenue growth, increased operating losses, and the necessity to reset commitments with Google Cloud temper the outlook. The Q&A reveals optimism about AI and robotics, but the absence of immediate financial benefits suggests a neutral outlook for the stock price in the short term.
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. While there are positives like improved EBITDA, cost reductions, and strong cash position, there are concerns about macroeconomic uncertainties, execution risks in new markets, and a reduction in biosecurity guidance. The Q&A section reveals potential in automation and RNA solutions but lacks clarity on timelines and geopolitical impacts. Overall, the mixed signals and lack of strong catalysts suggest a neutral stock price movement in the short term.
DNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
